<DOC>
	<DOCNO>NCT02988440</DOCNO>
	<brief_summary>A two part study determine maximum tolerate dose and/or recommend phase 2 dose PDR001 combination sorafenib patient advance hepatocellular carcinoma first line . There dose escalation part dose expansion part .</brief_summary>
	<brief_title>Study Safety Tolerability PDR001 Combination With Sorafenib Identify Maximum Tolerated Dose and/or Phase 2 Dose This Combination Advanced Hepatocellular Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm advanced ( unresectable and/or metastatic ) HCC Patients advance HCC amenable surgical locoregional treatment At least one measureable tumor lesion previously locally Patients current cirrhotic status ChildPugh class A ( 56 point total bilirubin &lt; 2 mg/dL doseescalation ) encephalopathy clinical ascites ( ascites control diuretic also exclude study ) . Patient Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Patient must meet required laboratory value screen Normal electrocardiogram screen Known fibrolamellar HCC , sarcomatoid HCC , mixed cholangiocarcinoma HCC Invasion main portal vein and/or tumor involvement 50 % liver ( applicable doseescalation part ) Patients Portalcaval shunt Prior concomitant systemic anticancer treatment advance disease Systemic chronic steroid therapy ( â‰¥ 10mg/day prednisone equivalent ) immunosuppressive therapy 7 day prior plan date first dose study treatment . Topical , inhale , nasal ophthalmic steroid allow . Cardiac cardiac repolarization abnormality Patients active Hepatitis B infection ( HBsAg positive ) receive antiviral treatment exclude Patients positive test hepatitis C ribonucleic acid ( HCV RNA ) Locoregional treatment within 4 week prior initiation study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HCC</keyword>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Hepatocellular carcinoma ( HCC )</keyword>
	<keyword>PDR001</keyword>
	<keyword>liver cancer</keyword>
	<keyword>immunotherapy liver</keyword>
	<keyword>malignant hepatoma</keyword>
	<keyword>Hepatocellular cancer</keyword>
	<keyword>advanced hepatocellular carcinoma ( HCC )</keyword>
	<keyword>advanced liver cancer</keyword>
	<keyword>liver cancer progression</keyword>
	<keyword>sorafenib</keyword>
	<keyword>anti-PD1</keyword>
	<keyword>first line</keyword>
</DOC>